SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-16-116438
Filing Date
2016-05-02
Accepted
2016-05-02 06:00:53
Documents
5
Period of Report
2016-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a16-9620_18k.htm 8-K 36081
2 EX-1.1 a16-9620_1ex1d1.htm EX-1.1 282629
3 EX-5.1 a16-9620_1ex5d1.htm EX-5.1 22859
4 EX-99.1 a16-9620_1ex99d1.htm EX-99.1 5996
5 EX-99.2 a16-9620_1ex99d2.htm EX-99.2 6716
  Complete submission text file 0001104659-16-116438.txt   355470
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 161609580
SIC: 2834 Pharmaceutical Preparations